June 09, 2020
IBRI and TBH Creative Win Gold Aster Award
We were pleased to partner with TBH Creative to move our 2018 Annual Report from print to online. TBH Creative took the PDF and transformed it into its own microsite...
June 03, 2020
IBRI RESEARCH PUBLISHED: Pre-clinical Evaluation of TYK2 Inhibitors for Human Beta Cell Protection in Type 1 Diabetes
Aims: Type 1 diabetes (T1D) is a chronic autoimmune disease leading to progressive loss of pancreatic beta cells. Interferon (IFN)-α plays a critical role in the crosstalk between...
May 29, 2020
IBRI IN THE NEWS: Pushing Hard for a COVID-19 Vaccine
The race is on.
Around the world, more than 80 vaccine projects are under development by pharmaceutical companies and university research laboratories scrambling to find a way to slow...
May 26, 2020
New Research Identifies Two Classes of Drugs that Could be Re-purposed for the Early Treatment of T1D
INDIANAPOLIS - Researchers from the Indiana Biosciences Research Institute (IBRI), a leading independent, industry-inspired applied research institute, and Université Libre de Bruxelles (ULB) Center for Diabetes Research, identified two classes...
May 13, 2020
IBRI RESEARCH PUBLISHED: Pancreatic ß-cells in Type 1 and Type 2 Diabetes Mellitus: Different Pathways to Failure
Loss of functional β-cell mass is the key mechanism leading to the two main forms of diabetes mellitus — type 1 diabetes mellitus (T1DM) and type 2 diabetes...
April 21, 2020
IBRI RESEARCH PUBLISHED: SUMOylation, a multifaceted regulatory mechanism in the pancreatic beta cells
SUMOylation is an evolutionarily conserved post-translational modification (PTM) that regulates protein subcellular localization, stability, conformation, transcription and enzymatic activity. Recent studies indicate that SUMOylation plays a key role...
April 16, 2020
IBRI IN THE NEWS: IBRI Names Scientific Director
INDIANAPOLIS - The Indiana Biosciences Research Institute has named Investigator Decio Eizirik as Scientific Director of the IBRI Diabetes Center. Eizirik will focus on recruiting early career investigators and defining...
April 15, 2020
IBRI Names Decio Eizirik Scientific Director of its IBRI Diabetes Center
INDIANAPOLIS, IND. – The Indiana Biosciences Research Institute (IBRI) is pleased to announce that it has named Investigator Decio Eizirik, MD, PhD, Scientific Director of its IBRI Diabetes Center (IDC)....
April 13, 2020
IBRI RESEARCH PUBLISHED: The T1D-associated lncRNA Lnc13 modulates human pancreatic ß cell inflammation by allele-specific stabilization of STAT1 mRNA
The mechanisms by which autoimmunity is amplified in type 1 diabetes (T1D) remain to be clarified, and the lack of this understanding hampers efforts to prevent or arrest the disease....
March 30, 2020
IBRI RESEARCH PUBLISHED: Hypusinated eIF5A is expressed in the pancreas and spleen of individuals with type 1 and type 2 diabetes
The gene encoding eukaryotic initiation factor 5A ( EIF5A ) is found in diabetes-susceptibility loci in mouse and human. eIF5A is the only protein known to contain hypusine...
First 1 2 3 4 5 ... Last